- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
InventisBio Co Ltd (688382)
The InventisBio share price today is 20.45, view SS 688382 stock exchange data. Track the latest InventisBio share price with real-time updates on 688382 stock performance including market cap, day range, 52-week range and dividend yield. Access 688382 charts, earnings dates and analyst estimates to support your investment decisions.
Shanghai
Currency in CNY
20.45
+2.45(+13.61%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.45
20.69
52 wk Range
15.58
49.68
688382 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.4520.69
52 wk Range
15.5849.68
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
688382 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
32.55
Upside
+59.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 32.55
(+59.17% Upside)
Earnings
Latest Release
29-04-2026
EPS / Forecast
-0.08 / --
Revenue / Forecast
43M / --
Compare 688382 to Peers and Sector
Metrics to compare | 688382 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688382PeersSector | |
|---|---|---|---|---|
P/E Ratio | −34.3x | −12.0x | −0.4x | |
PEG Ratio | 0.86 | 0.11 | 0.00 | |
Price/Book | 7.0x | 4.4x | 2.6x | |
Price / LTM Sales | 145.3x | 10.9x | 3.0x | |
Upside (Analyst Target) | 76.6% | 43.7% | 53.6% | |
Fair Value Upside | Unlock | −1.4% | 7.6% | Unlock |
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. The company also develops D—2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout. In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the InventisBio (688382) Share Price Today?
The InventisBio share price today is 20.45.
What is the current InventisBio (688382) share price and day range?
As of 01-07-2026, the InventisBio share price is 20.45, with a previous close of 18.00. The share price has ranged from 17.45 to 20.69 today, while the 52-week range spans from 15.58 to 49.68.
What Is the InventisBio Market Cap?
As of today, InventisBio market cap is 10.41B.
What Is the InventisBio (688382) Share Price Target?
The average 12-month share price target for InventisBio is 32.55, with a high estimate of 32.55 and a low estimate of 32.55. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +59.17% Upside potential.
What Is InventisBio's Earnings Per Share (TTM)?
The InventisBio EPS (TTM) is -0.53.
When Is the Next InventisBio Earnings Date?
InventisBio will release its next earnings report on 20-08-2026.
From a Technical Analysis Perspective, Is 688382 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does InventisBio Trade On?
InventisBio is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for InventisBio?
The stock symbol for InventisBio is "688382."
How Many Times Has InventisBio Stock Split?
InventisBio has split 0 times.
How Many Employees Does InventisBio Have?
InventisBio has 182 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.